Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4M Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first test, GenoPredicta and further development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases. In addition to the successful raise, Predicta also announced the appointment of Brian McKernan as CEO.